Pfizer Inc. Issues Statement on ZoetisTM IPO

  Pfizer Inc. Issues Statement on ZoetisTM IPO

Business Wire

NEW YORK -- February 1, 2013

Pfizer Inc. (NYSE: PFE) today announced that its former animal health business
unit, now a standalone company named Zoetis^TM, began trading on the New York
Stock Exchange under the ticker symbol “ZTS.”

“This is a proud moment for all Zoetis and Pfizer employees,” said Ian Read,
chairman and chief executive officer of Pfizer. “With the Zoetis initial
public offering, we are creating the largest standalone company fully devoted
to animal health medicines and vaccines. For Pfizer, we are better positioned
to focus on our core business as an innovative biopharmaceutical company, by
unlocking value from the animal health business that will return value to
Pfizer shareholders.”

Building on a 60-year history as the animal health business of Pfizer, Zoetis
discovers, develops, manufactures and markets veterinary vaccines and
medicines for livestock and companion animals. Pfizer announced in 2012 that
it would pursue an initial public offering (IPO) of a minority ownership stake
in its animal health business unit as part of its long-term strategy to focus
on the company’s core biopharmaceuticals business.

Serving health needs across eight animal species, including farm animals such
as cattle, pigs, poultry, sheep and fish, and companion animals such as dogs,
cats and horses, Zoetis’ diversified portfolio of more than 300 product lines
spans five categories: vaccines, parasiticides, anti-infectives, medicated
feed additives, and other pharmaceuticals for veterinarians and livestock
producers.

“Since 1952, our animal health business has served the needs of those who
raise and care for animals with high quality medicines and vaccines. Now, as
Zoetis, it is well positioned to pursue the growth strategies that will
enhance its global reach and drive further commercial success. We congratulate
our Zoetis colleagues on this important milestone,” said Read.

This press release shall not constitute an offer to sell or the solicitation
of an offer to buy nor shall there be any sale of these securities in any
state or jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the securities laws of
any state or jurisdiction.

About Pfizer Inc.: Working together for a healthier world®

At Pfizer, we apply science and our global resources to improve health and
well-being at every stage of life. We strive to set the standard for quality,
safety and value in the discovery, development and manufacturing of medicines
for people and animals. Our diversified global health care portfolio includes
human and animal biologic and small molecule medicines and vaccines, as well
as many of the world’s best-known consumer products. Every day, Pfizer
colleagues work across developed and emerging markets to advance wellness,
prevention, treatments and cures that challenge the most feared diseases of
our time. Consistent with our responsibility as the world’s leading
biopharmaceutical company, we also collaborate with health care providers,
governments and local communities to support and expand access to reliable,
affordable health care around the world. Formore than 150 years,Pfizer has
worked to makea difference for all who rely on us.

DISCLOSURE NOTICE: The information contained in this release is as of February
1, 2013. Pfizer assumes no obligation to update forward-looking statements
contained in this release as the result of new information or future events or
developments.

This release contains forward-looking information that involves substantial
risks and uncertainties about the initial public offering of shares of Class A
common stock of Zoetis Inc. Such risks and uncertainties include, among other
things, risks relating to Zoetis as a standalone business as the result of the
variables and uncertainties inherent in business, financial and operating
performance, including, among other things, competitive developments and
general economic, political, business, industry, regulatory and market
conditions; and the potential for disruption to Zoetis as the result of the
initial public offering. A further description of risks and uncertainties can
be found in Zoetis’ Registration Statement on Form S-1(File No. 333-183254),
as amended, as filed with the Securities and Exchange Commission.

All content set forth in this communication is subject to consultation with
works councils, unions and employee representatives as required by and subject
to local laws and regulations.

Contact:

Pfizer Inc.
Media:
Joan Campion, 212-733-2798
joan.campion@pfizer.com
or
Investor:
Chuck Triano, 212-733-3901
charles.e.triano@pfizer.com
 
Press spacebar to pause and continue. Press esc to stop.